Iovance Biotherapeutics (IOVA) 10-K2013 FY Annual report

Filed: 28 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Adaptimmune, Albuquerque, analyzed, arose, ASC, assumption, ASU, automobile, Battlefield, Baxter, Bender, broker, buy, calculated, carryforward, Celgene, cervical, chairperson, colon, condensed, creditor, CT, culture, cumbersome, document, empowered, enriched, eradicated, erratic, Europe, father, freely, frequently, frontline, half, harvested, Herbert, IDM, incidence, Inflation, Israel, Joseph, Kite, lambrolizumab, LBIO, Mexico, Nexell, nivolumab, official, parity, payroll, perception, pf, Pharma, Pink, preconditioned, pro, proof, QB, ramp, rata, ready, Reconciliation, repeal, resold, riskiest, Roth, salesperson, Sheba, shift, shortened, sound, spent, stem, sudden, suppressive, surrender, topic, tradable, tradeable, unrecognized, unwanted, usage, winding

Removed: abandoned, administer, applied, authorizing, bank, biomedical, Black, body, called, Canadian, capable, carrying, Cayman, chemistry, confirmation, confirmatory, consummated, customer, delivery, descent, disclosing, discourage, effecting, exceeding, expertise, explaining, financed, FINRA, funded, Genentech, Geron, hierarchy, impairment, imposed, intangible, invalidate, investigator, kill, limitation, manage, merged, Nottingham, operational, orally, partly, people, performing, preserve, profit, prospectively, recoverable, replicate, requested, Reserve, restricting, serving, shared, sixty, smaller, spouse, strain, suitability, sustainable, therewith, train, uncertainty, unexpected, unique, unsuccessful, wholly, wide, worth, writing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IOVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Handelman, Chief Financial Officer of Lion Biotechnologies, Inc. (the “Company”), hereby certify that, to the best of my knowledge:

(i) the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2013 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.



Date: March 27, 2014	By:	/s/ MICHAEL HANDELMAN
		Name: Michael Handelman
		Title: Chief Financial Officer (Principal Financial Officer)